Effect of Levothyroxine Replacement on Lipid Profile and Intima-Media Thickness in Subclinical Hypothyroidism: A Double-Blind, Placebo- Controlled Study

AbstractThis study evaluated the effects of Mg administration on carotid intima–media thickness (CIMT), glycaemic control and markers of cardio-metabolic risk in diabetic haemodialysis (HD) patients. This randomised, double-blind, placebo-controlled clinical trial was conducted in fifty-four diabetic HD patients. Participants were randomly divided into two groups to take either 250 mg/d Mg as magnesium oxide (n27) or placebo (n27) for 24 weeks. Mg supplementation resulted in a significant reduction in mean (P<0·001) and maximum levels of left CIMT (P=0·02) and mean levels of right CIMT (P=0·004) compared with the placebo. In addition, taking Mg supplements significantly reduced serum insulin levels (β=–9·42 pmol/l; 95% CI –14·94, –3·90;P=0·001), homoeostasis model of assessment-insulin resistance (β=–0·56; 95 % CI –0·89, –0·24;P=0·001) and HbA1c (β=–0·74 %; 95 % CI –1·10, –0·39;P<0·001) and significantly increased the quantitative insulin sensitivity check index (β=0·008; 95 % CI 0·002, 0·01;P=0·002) compared with the placebo. In addition, Mg administration led to a significant reduction in serum total cholesterol (β=–0·30 mmol/l; 95% CI –0·56, –0·04;P=0·02), LDL-cholesterol (β=–0·29 mmol/l; 95% CI –0·52, –0·05;P=0·01), high-sensitivity C-reactive protein (hs-CRP) (P<0·001) and plasma malondialdehyde (MDA) (P=0·04) and a significant rise in plasma total antioxidant capacity (TAC) levels (P<0·001) compared with the placebo. Overall, we found that taking Mg for 24 weeks by diabetic HD patients significantly improved mean and maximum levels of left and mean levels of right CIMT, insulin metabolism, HbA1c, total cholesterol and LDL-cholesterol, hs-CRP, TAC and MDA levels.

Download Full-text

The Multispecies Probiotic Effectively Reduces Homocysteine Concentration in Obese Women: A Randomized Double-Blind Placebo-Controlled Study

Journal of Clinical Medicine ◽

10.3390/jcm9040998 ◽

2020 ◽

Vol 9 (4) ◽

pp. 998 ◽

Cited By ~ 2

Author(s):

Karolina Majewska ◽

Matylda Kręgielska-Narożna ◽

Hieronim Jakubowski ◽

Monika Szulińska ◽

Paweł Bogdański

Keyword(s):

Oxidative Stress ◽

Lipid Profile ◽

Controlled Trial ◽

Density Lipoprotein ◽

Controlled Study ◽

Obese Women ◽

Bacterial Strains ◽

Double Blind ◽

Double Blind Placebo ◽

Homocysteine Concentration

Dysregulated metabolism of homocysteine (Hcy) is associated with obesity. Supplementation with probiotics can potentially be a natural therapeutic method for metabolic disorders. The precise mechanism in which microbiota affect Hcy metabolism in obese individuals is still unknown. The aim of this study was to evaluate the effects of a 12-week supplementation with a multispecies probiotic on Hcy levels, oxidative stress, inflammation and lipid profile in obese patients. This randomized double-blind placebo-controlled trial was performed on 50 obese women (aged 45–70 years). Subjects were randomly assigned to take either a multispecies probiotic supplement (n = 25) or placebo (n = 25) for 12 weeks. The probiotic contained nine bacterial strains containing 2.5 × 109 CFU/g. Biochemical and anthropometric measurements were carried out at baseline and after 12 weeks of intervention. At the end of the study, a significant decrease in Hcy, tumor necrosis factor α (TNF-α), total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and triglyceride (TG) levels were observed in the probiotic group. The amelioration of total antioxidant status (TAS) was also observed. The 12-week supplementation of the multispecies probiotic (Ecologic® BARIER) effectively reduced Hcy concentration, oxidative stress and inflammation, and improved the lipid profile. These multidirectional effects can potentially reduce cardiometabolic risks.

Download Full-text

Abstract 577: Medical Marijuana Use: Effect on Lipid Metabolism and Atherosclerosis

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/atvb.35.suppl_1.577 ◽

2015 ◽

Vol 35 (suppl_1) ◽

Author(s):

Carolina Ponce Orellana ◽

Paola Roldan ◽

Wilmer Sibbitt ◽

Clifford Qualls ◽

Carlos Roldan

Keyword(s):

Lipid Metabolism ◽

Lipid Profile ◽

Lupus Erythematosus ◽

Case Reports ◽

Medical Marijuana ◽

Intima Media Thickness ◽

Marijuana Use ◽

Controlled Study ◽

Media Thickness ◽

Medical Marijuana Use

Background: Dyslipidemia and aortic (Ao) and carotid (Ca) atherosclerosis are common in systemic lupus erythematosus (SLE) and are associated with increased morbidity and mortality. Medical use of Marijuana is common in SLE. Marijuana use has been associated with stroke and myocardial infarction in isolated case reports and limited and retrospective series. In contrast, Marijuana in atherogenic animal models has resulted in favorable lipid metabolism and inhibition of atherosclerosis. However, there are limited data on the effect of medical Marijuana on the lipid profile and atherosclerosis in humans. Methods: 76 SLE patients (69 women, age 38 ± 12 years) underwent laboratory evaluations including lipid profile [total cholesterol, LDL, HDL, and triglycerides levels in mg/dL] and Ca ultrasonography and transesophageal echocardiography for assessment of Ca and Ao atherosclerosis, respectively. Atherosclerosis was defined as intima-media thickening (mean intima-media thickness in 26 healthy controls+2SD) or plaques (as >50% focal intima-media thickening as compared with surrounding walls). Fifteen (20%) patients were regular users of medical Marijuana (≥3 times per week for ≥1 year). Results: As shown in Table 1, Marijuana users versus non-users had lower total and LDL cholesterol (both p ≤0.006) and triglycerides (p=0.13). Also, Ao and Ca intima media thickness, intima-media thickening, or plaques were similar in users and non-users. Conclusions: Medical Marijuana use in SLE patients may not have a detrimental effect on lipid metabolism or atherogenesis. These findings are preliminary and need confirmation in a larger controlled study.

Download Full-text